ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Artificial intelligence in pancreatic cancer: applications in early detection, tumor staging, and survival prediction-a comprehensive review.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the rapidly developing world, artificial intelligence (AI) is one of the emerging applications in the medical domain. Early detection of cancer is one of the most difficult processes, especially when it comes to the differentiation of cancer's structure, length, and size. AI methodology offers innovations and decision-making applicable to specific processes like data collecting, management, results, and conclusions. Due to the lack of particular indicators, the difficult location of the pancreas, and the absence of early symptoms, pancreatic cancer (PC) is difficult to identify with low and late analysis. However, the imaging approach is slightly improving analysis, but there is still potential for enhancement in systematizing guidelines. This comprehensive review will mainly focus on various applications of AI in pancreatic cancer diagnosis. Furthermore, this review presents various architectures based on machine learning (ML) and deep learning (DL) methods for applications such as early detection, classification, tumor staging, and pancreatic cancer survival prediction. In order to better comprehend challenging cases, clinical practitioners can benefit from the supplementary information and useful recommendations provided by various techniques. Finally, this review potentially analyzes the advantages and drawbacks present in pancreatic cancer. This review provides an overview of research based on AI methods and algorithms that provide superior performance from a variety of pancreatic cancer patients while also providing viable future perspectives with significant advancements to overcome drawbacks in previous research and provide enhanced performance, stating their effectiveness and robustness analysis.
Indexed as
Identifiers
42126789What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.